» Articles » PMID: 28291232

Comprehensive RNA-seq Transcriptomic Profiling in the Malignant Progression of Gliomas

Overview
Journal Sci Data
Specialty Science
Date 2017 Mar 15
PMID 28291232
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas are the most common and lethal intracranial tumours. RNA sequencing technologies and advanced data analyses recently enabled the characterization of transcriptomic information, including protein-coding gene expression, non-coding gene expression, alternative splicing, and fusion gene detection, to facilitate detection of diseases and altered phenotypes. As a part of the Chinese Glioma Genome Atlas (CGGA) project, our aim was to delineate comprehensive transcriptome profiling in the malignant progression of human gliomas. Three hundred twenty five gliomas with different grades were collected over the past twelve years. Using the Illumina HiSeq 2,000 system, over 92 million high quality 101-bp paired-end reads were generated per sample, yielding a total of 30 billion reads. This comprehensive dataset will be useful to deepen the comprehensive understanding of gliomas, providing an opportunity to generate new therapies, diagnoses, and preventive strategies.

Citing Articles

A computational framework for extracting biological insights from SRA cancer data.

Guimaraes P, Carvalho M, Ruiz J Sci Rep. 2025; 15(1):8117.

PMID: 40057525 PMC: 11890766. DOI: 10.1038/s41598-025-91781-8.


Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma.

Wang H, Liu Z, Peng Z, Lv P, Fu P, Jiang X PLoS One. 2025; 20(2):e0316552.

PMID: 39903772 PMC: 11793784. DOI: 10.1371/journal.pone.0316552.


Bulk and single-cell transcriptome revealed the metabolic heterogeneity in human glioma.

Xiao Y, Zhao M, Wang R, Liu L, Xiang C, Li T Heliyon. 2025; 11(1):e41241.

PMID: 39844970 PMC: 11750464. DOI: 10.1016/j.heliyon.2024.e41241.


BRAT1 - a new therapeutic target for glioblastoma.

Haydo A, Schmidt J, Crider A, Kogler T, Ertl J, Hehlgans S Cell Mol Life Sci. 2025; 82(1):52.

PMID: 39833546 PMC: 11747058. DOI: 10.1007/s00018-024-05553-0.


Prognostic value of CTF1 in glioma and its role in the tumor microenvironment.

He J, Guo J, Sun P Transl Cancer Res. 2025; 13(12):6862-6879.

PMID: 39816535 PMC: 11730202. DOI: 10.21037/tcr-24-1258.


References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Chen H, Yu K, Tang X, Bao Z, Jiang T, Fan X . Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions. FEBS Lett. 2015; 589(13):1437-43. DOI: 10.1016/j.febslet.2015.04.032. View

3.
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X . CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016; 375(2):263-273. DOI: 10.1016/j.canlet.2016.01.024. View

4.
Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A . Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25(18):1915-27. PMC: 3185964. DOI: 10.1101/gad.17446611. View

5.
Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View